252 related articles for article (PubMed ID: 10878287)
1. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.
Souness JE; Aldous D; Sargent C
Immunopharmacology; 2000 May; 47(2-3):127-62. PubMed ID: 10878287
[No Abstract] [Full Text] [Related]
2. The next generation of PDE4 inhibitors.
Huang Z; Ducharme Y; Macdonald D; Robichaud A
Curr Opin Chem Biol; 2001 Aug; 5(4):432-8. PubMed ID: 11470607
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last?
Kerstjens HA; Timens W
Am J Respir Crit Care Med; 2003 Oct; 168(8):914-5. PubMed ID: 14555456
[No Abstract] [Full Text] [Related]
4. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.
Kroegel C; Foerster M
Expert Opin Investig Drugs; 2007 Jan; 16(1):109-24. PubMed ID: 17155857
[TBL] [Abstract][Full Text] [Related]
5. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
Xia XD; Dai YR; Xu ZJ
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan; 27(1):57-9. PubMed ID: 14989829
[No Abstract] [Full Text] [Related]
6. Highly potent PDE4 inhibitors with therapeutic potential.
Ochiai H; Ohtani T; Ishida A; Kusumi K; Kato M; Kohno H; Kishikawa K; Obata T; Nakai H; Toda M
Bioorg Med Chem Lett; 2004 Jan; 14(1):207-10. PubMed ID: 14684329
[TBL] [Abstract][Full Text] [Related]
7. COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1.
Celli B
Chest; 2006 Jan; 129(1):5-6. PubMed ID: 16424403
[No Abstract] [Full Text] [Related]
8. The potential of PDE4 inhibitors in respiratory disease.
Spina D
Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):231-6. PubMed ID: 15379590
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.
Doggrell SA
Expert Opin Pharmacother; 2006 Mar; 7(4):485-8. PubMed ID: 16503820
[No Abstract] [Full Text] [Related]
10. Phosphodiesterases: the journey towards therapeutics.
Torphy TJ; Page C
Trends Pharmacol Sci; 2000 May; 21(5):157-9. PubMed ID: 10885973
[No Abstract] [Full Text] [Related]
11. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Smith VB; Spina D
Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
[TBL] [Abstract][Full Text] [Related]
12. PDE4D-deficient mice knock the breath out of asthma.
Giembycz M
Trends Pharmacol Sci; 2000 Aug; 21(8):291-2. PubMed ID: 10918631
[No Abstract] [Full Text] [Related]
13. Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.
Charpiot B; Brun J; Donze I; Naef R; Stefani M; Mueller T
Bioorg Med Chem Lett; 1998 Oct; 8(20):2891-6. PubMed ID: 9873643
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
15. A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
Chambers RJ; Abrams K; Castleberry TA; Cheng JB; Fisher DA; Kamath AV; Marfat A; Nettleton DO; Pillar JD; Salter ED; Sheils AL; Shirley JT; Turner CR; Umland JP; Lam KT
Bioorg Med Chem Lett; 2006 Feb; 16(3):718-21. PubMed ID: 16263279
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
17. Quaternary substituted PDE IV inhibitors II: the synthesis and in vitro evaluation of a novel series of gamma-lactams.
Hulme C; Moriarty K; Huang FC; Mason J; McGarry D; Labaudiniere R; Souness J; Djuric S
Bioorg Med Chem Lett; 1998 Feb; 8(4):399-404. PubMed ID: 9871693
[TBL] [Abstract][Full Text] [Related]
18. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
Sanz MJ; Cortijo J; Morcillo EJ
Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
[TBL] [Abstract][Full Text] [Related]
19. Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.
Amata E; Bland ND; Hoyt CT; Settimo L; Campbell RK; Pollastri MP
Bioorg Med Chem Lett; 2014 Sep; 24(17):4084-9. PubMed ID: 25127163
[TBL] [Abstract][Full Text] [Related]
20. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.
Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R
Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695
[No Abstract] [Full Text] [Related]
[Next] [New Search]
